Regarding “Use of abdominal aortic endovascular prostheses in France from 1999 to 2001”  by Becquemin, J.P et al.
LETTERS TO THE EDITORRegarding “Use of abdominal aortic endovascular
prostheses in France from 1999 to 2001”
We read with interest the article by Ricco et al about the use of
stent grafts for abdominal aortic aneurysms (AAAs) in France (J
Vasc Surg 2003;38:1273-81). The main conclusion of the article is
that endovascular aneurysm repair (EVAR) is not in compliance
with the French rules.
As French academic vascular surgeons and interventional ra-
diologists, we do not think that the report supports this view and
we want to underline the weakness of methodology, to contest
some of the conclusions, and to express worry about the future of
stent grafts in this country.
The study was ordered by the French National Health Insur-
ance Fund for Salaried Workers (CNAMTS, French acronym)
which is the public organism responsible for reimbursements for
health care. CNAMTS cannot be considered as an agency “inde-
pendent of administrative, commercial or political interests, as
Ricco et al state.” Guidelines from the French Agency for Accred-
itation and Evaluation in Health (ANAES, French acronym) (Ta-
ble I) are wrongly quoted. For example, the recommendation of
the ANAES1 in 1999 did not mention the diameter of the aneu-
rysm as criteria for patient selection. It must be remembered that
the United Kingdom Small Aneurysm Trial and the Aneurysm
Detection and Management Veterans Affairs Cooperative Study
Group trial were published in 2002, three years later. Ricco et al
write, “Patient data should be reported to a national registry.” A
registry, aimed at assessing material safety issues, was not set up by
the French Agency for Sanitary Safety of Health Products (AFS-
SAPS, French acronym) until 2002.2 In the absence of a national
registry, many patients’ data were sent to the Eurostar registry
which, as far as we are aware of, was not recognized by the
collectors of data. From an organizational point of view, data were
collected by permanent medical advisors of the agency who have
no training in clinical research and were rarely familiar with vascular
diseases. In many institutions, patients’ files were rapidly over-
looked, and, contrary to what it is stated, study findings in individ-
ual centers were not presented to the surgeon, who then was not
enabled to “provide corrections or addendum that he or she
deemed necessary,” as Ricco et al aver. It is thus understandable
that the study includes many misstatements. For example, stent
graft for iliac aneurysms (with obviously smaller diameter) was not
considered separately in the analysis. Also, type II endoleaks in the
follow-up were considered as complications. Finally, contrary to
elementary publications rules, this article has been published with-
out the awareness, review, and approval of the physicians from
whom the data have been obtained. We also regret that the
CNAMTS has missed the opportunity to assess open repair of AAA
as well. Since a lot of effort and money have been spent to verify
files of patients in every vascular department, it would have been
relatively easy to check the indications, mortality, and complica-
tions rate with open repair. This article would have looked less
biased.
First- and second-generation stent grafts evaluated in this
study were not optimal. However, despite their imperfection,
patient’s lives have been saved during the postoperative period.
The mortality of the technique shown by the study but not
underlined by the authors was 2.7% in 30 postoperative days and
5.3% for the entire study, which is quite acceptable given the
relatively high number of high-risk patients included (63%). As far
as we can observe from previously published articles,3-6 long-term
results in terms of survival are at least equivalent to open repair. If
true, the lack of surveillance in the 18% of patients mentioned in
the Ricco article is worrisome. We strongly agree that given the
relative long-term uncertainty of the endovascular technique and1358the relatively frequent need for secondary intervention to prevent
failure, physicians and patients must be aware and informed of the
absolute need for a proper follow-up. The burden of this follow-up
must be accepted by both parties.
The ANAES in 1999 and the AFSSAPS in 2001 have stated
that trials were needed to assess the safety and efficiency of stent
grafts as compared with open repair. Such a trial has been set up in
France. Unfortunately, the refusal of the CNAMTS to reimburse
for grafts and physician’s fees, even in the framework of an inde-
pendently and well-controlled research setting, threaten the run-
ning of the study.
One can then easily understand why in France, with a total
population of 60 million people, 20% above their sixties, only 500
grafts are implanted each year. It is a dramatic contrast with the rest
of Europe and USA in which, respectively, 14,000 and 17,000
stent grafts were implanted last year.
In summary, progress in medicine needs positive behavior and
fair analysis of data. We are convinced that appropriate randomized
trials will solve the question of the interest and limits of EVAR. It
is also the best and most ethical way “to protect patient’s rights.”
We hope that the current CNAMTS thoughts and actions will not
kill this technique in France, neither in properly designed trials nor
in high-risk patients.
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Reply
Regarding Becquemin et al’s letter criticizing our article about
endovascular aneurysm repair (EVAR) in France, we wish to clarify
two points and then respond to several specific comments. The first
clarification involves the conclusion of the study. We did not, as
stated in the letter, conclude that “EVAR is not in compliance with
the French rules.” We found that EVAR had not been properly
evaluated in France and that potentially valuable data had been
lost. The second point requiring clarification involves the charge
that the physicians involved were not informed of the conclusions
of our study. In fact, a more exhaustive report was published and
sent to all French vascular surgeons and relevant scientific societies
in October 2002. It is interesting to note that this information
caused less reaction when presented in French within a strictly
national context than in English in a major international journal.
Becquemin et al wrote that the French National Health Insur-
ance Fund for Salaried Workers (CNAMTS, French acronym)
cannot be considered as “independent of administrative, commer-
cial, or political interests.” Here a little background might be
useful. The CNAMTS covers 80% of the French population, with
an estimated global budget of US$ 171 billion for 2004. Since all
decisions concerning health care coverage are taken by the govern-
ment, the CNAMTS has no administrative or political conflicts of
interest. Nor can any commercial bias be suspected since, unlike
many health care professionals, CNAMTS personnel are not solic-
ited by industry to promote products.
The letter also stated that “the medical advisors of the
CNAMTS have no training in clinical research and were rarely
familiar with vascular diseases.” This statement aimed at discredit-
ing the physicians of the CNAMTS is unfair and untrue. CNAMTS
medical advisors are trained to investigate medical practices using
precisely defined techniques suited to the topic of inquiry. The data
of this study were obtained by consulting medical charts. Since this
study was not performed for legal purposes, there was no cross-
examination procedure. However, results were communicated
back to the practitioners through reports made by regional repre-
sentatives of the CNAMTS medical service.
The treatment standards used by CNAMTS medical advisors
were not contested by any practitioners. The most important
standard was aneurysm diameter. In this regard it should be
pointed out that Becquemin et al’s letter contains two important
chronological errors. First, the ANAES report1 was published in
June 1999 before the beginning of the CNAMTS investigation
and specifically recommended treatment for aneurysms greater
than 5 cm and surveillance for smaller aneurysms. The second
chronological error involves the date of publication of the United
Kingdom Small Aneurysm Trial2, which was 1998 and not 2002.
In June 1999 it is unlikely that any French practitioner was
unaware of the recommended cutoff for surveillance and treat-
ment. Yet 30% of EVAR procedures performed in France from
June 1999 to May 2001 involved aneurysms smaller than 5 cm.
This percentage would not change significantly if the few cases
involving isolated iliac aneurysm were withdrawn.
As Becquemin et al pointed out, our study did not include a
control group or compare mortality and morbidity after surgeryand EVAR. Our response to this critique is twofold. First, the
purpose of the study was not to compare EVAR and surgery, but to
know if EVAR had been evaluated properly. Second, it is well
known that most comparative studies on this point are biased
because the criteria of selection for EVAR are not the same as those
for “surgical” patients.
Becquemin et al fault us for not recognizing the Eurostar
register. They claim that the recommendations for the creation of
a national register were not issued before 2002 and that in the
meantime many patients treated in France between 1999 and 2001
were included in the Eurostar register. This critique overlooks the
fact that in 1999 a follow-up register was considered mandatory by
the ANAES and by the French Society for Vascular Surgery. In
fact, despite these recommendations only 192 of the stent grafts
placed in France before 2001 were reported in the Eurostar regis-
ter.3
The suggestion that the CNAMTS is trying to block the
development of new technologies in France is again unfair and
untrue. The CNAMTS covers the total expenditures of French
university hospitals including 13% devoted to teaching and re-
search. Specifically regarding EVAR, the CNAMTS has been cov-
ering procedures performed in the framework of trials since 1999.
In fact, the CNAMTS has simply applied French Law for clinical
research and specific decisions of the Health Ministry concerning
EVAR. A major factor in the adverse decisions taken by the Health
Ministry has been the negative effect that the undisciplined behav-
ior of French practitioners has had on administrative and political
officials.
In conclusion, it might be well to open this French debate up
to an international context. As Frank Veith wrote in his invited
commentary about our article, “it is likely that physician and
surgeon behavior is not going to differ greatly in the rest of the
world.” The ASERNIP-S report4 made for the Australian Govern-
ment Department of Health and Aging supports this view by
showing that 14.2% of patients who underwent EVAR did not
undergo adequate follow-up and that 27.2% had aneurysms with
an initial diameter less than or equal to 5 cm. These findings are
quite similar to ours.
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